These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last? DeAngelo DJ; Stein EM; Ravandi F Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736 [TBL] [Abstract][Full Text] [Related]
24. New treatment for acute myelogenous leukemia. DiNardo CD; Cortes JE Expert Opin Pharmacother; 2015 Jan; 16(1):95-106. PubMed ID: 25480777 [TBL] [Abstract][Full Text] [Related]
25. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Tsimberidou A; Estey E; Cortes J; Thomas D; Faderl S; Verstovsek S; Garcia-Manero G; Keating M; Albitar M; O'Brien S; Kantarjian H; Giles F Cancer; 2003 Mar; 97(6):1481-7. PubMed ID: 12627513 [TBL] [Abstract][Full Text] [Related]
26. [Recent progress in the treatment of acute leukemia]. Kimura Y Gan To Kagaku Ryoho; 2003 Jul; 30(7):895-901. PubMed ID: 12894700 [TBL] [Abstract][Full Text] [Related]
27. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963 [TBL] [Abstract][Full Text] [Related]
28. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084 [TBL] [Abstract][Full Text] [Related]
29. New agents for the treatment of acute myeloid leukemia. Tallman MS Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128 [TBL] [Abstract][Full Text] [Related]
30. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Liang DC; Chan TT; Lin KH; Lin DT; Lu MY; Chen SH; Liu HC; Lin MT; Lee MT; Shu SG; Chang TK; Chen JS; Hsiao CC; Hung IJ; Hsieh YL; Chen RL; Cheng SN; Chang WH; Lee CH; Lin KS Leukemia; 2006 Jan; 20(1):136-41. PubMed ID: 16281075 [TBL] [Abstract][Full Text] [Related]
31. Acute Myeloid Leukemia: Past, Present, and Prospects for the Future. Short NJ; Ravandi F Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S25-9. PubMed ID: 27521321 [TBL] [Abstract][Full Text] [Related]
32. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Murphy T; Yee KWL Expert Opin Pharmacother; 2017 Nov; 18(16):1765-1780. PubMed ID: 29017371 [TBL] [Abstract][Full Text] [Related]
33. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study. Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579 [TBL] [Abstract][Full Text] [Related]
34. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA; Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319 [TBL] [Abstract][Full Text] [Related]
35. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Luskin MR; DeAngelo DJ Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942 [TBL] [Abstract][Full Text] [Related]
36. Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis. Feng X; Lan H; Ruan Y; Li C Hematology; 2018 Oct; 23(9):581-589. PubMed ID: 29516766 [TBL] [Abstract][Full Text] [Related]
37. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828 [TBL] [Abstract][Full Text] [Related]
38. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA; J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813 [TBL] [Abstract][Full Text] [Related]
39. Acute myeloid leukemia: 2013 update on risk-stratification and management. Estey EH Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416 [TBL] [Abstract][Full Text] [Related]